Fyroflex SOL-DP

Endpoint summary

Description of key information

The following Acute toxicity studies are available:
Acute Oral  toxicity study (rat)
Acute dermal toxicity study (rabbit)
Acute inhalation toxicity (rats)

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion

Dose descriptor:

LD50

Value:

5 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion

Dose descriptor:

LC50

Value:

5 000 mg/m³

Acute toxicity: via dermal route

Endpoint conclusion

Dose descriptor:

LD50

Value:

5 000 mg/kg bw

Additional information

Acute oral (male and female rats), acute dermal (male and female rabbits) and acute inhalation (male and female rats) toxicity studies were performed with Fyrolflex SOL-DP.

Following either oral or dermal administration no mortalities were observed in either sex at 5000 mg/kg, no signs of systemic toxicity were noted during clinical observations and no abnormalities were noted during necropsy.

Following the 4 hours inhalation exposure to 5.23 mg/l aerosol SOL-DP, no exposure related findings were shown in clinical signs of both sexes and only a minor effect on bodyweight profile was noted. Limited necropsy findings were observed in the lungs and mandibular lymph nodes of some animals, and the lung: body weight ratios were considered to be normal.

 

Justification for classification or non-classification

The above results triggered no classification under the EEC criteria for classification and labelling requirements for Dangerous Substances and Preparations (67/548/EEC) and the CLP Regulation (EC No 1272/2008). Therefore, Fyrolflex SOL-DP is not classified for acute toxicity.